Imaging assessment of tumor densities and sizes following pazopanib treatment for central nervous system solitary fibrous tumors with multiple extracranial metastases: A case series
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Central nervous system (CNS) solitary fibrous tumors (SFTs) are rare but aggressive, often metastasizing to extracranial regions, with no established treatments apart from surgery. Pazopanib, a multikinase angiogenesis inhibitor, is used to treat extracranial SFTs; however, its efficacy for treating CNS SFTs remains unclear. To address this issue, the efficacy of pazopanib was investigated, focusing on tumor density and size in CNS SFTs with extracranial metastases after initiation, interruption or resumption of pazopanib treatment. The present study retrospectively reviewed 3 consecutive cases of CNS SFTs showing extracranial metastases that were referred to Kochi Health Sciences Center (Kochi, Japan) between January 2018 and April 2024 and were treated with pazopanib. All measurable lesions observed via contrast-enhanced computed tomography (CT; 50 lesions) and magnetic resonance imaging (MRI; 21 lesions) were evaluated. Cases 2 and 3, meeting the Choi criteria, showed stable disease and achieved partial response after pazopanib initiation, respectively. In Case 1, both intracranial and extracranial tumor CT densities decreased after initiation and resumption of pazopanib treatment. However, both tumor CT sizes increased after interruption of pazopanib treatment. In Case 2, MRI revealed decreases and increases in the intracranial tumor size after initiation and interruption, respectively. Notably, pazopanib interruption caused rapid infratentorial tumor growth and death. Case 3 showed decreased extracranial tumor CT densities and sizes after pazopanib initiation, with pazopanib administered for 3.5 years. Thus, pazopanib may offer the potential to control both intracranial and extracranial tumors in patients with CNS SFTs with extracranial metastasis; however, treatment interruption requires careful consideration.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Imaging assessment of tumor densities and sizes following pazopanib treatment for central nervous system solitary fibrous tumors with multiple extracranial metastases: A case series
- Date Crossref
- 06/11/2024
- Éditeur
- Spandidos Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Kochi pays non établi dans la noticeUniversité ou école supérieure
-
Kochi Health Sciences Center pays non établi dans la noticeStructure de recherche
-
Hata Kenmin Hospital Department of Neurosurgery pays non établi dans la noticeÉtablissement de santé
-
Chikamori Hospital Department of Neurosurgery pays non établi dans la noticeÉtablissement de santé
-
Department of Neurosurgery pays non établi dans la noticeInstitution
-
Department of Orthopedic Surgery pays non établi dans la noticeInstitution
-
Department of Radiology pays non établi dans la noticeInstitution
University of Kochi, Kochi Health Sciences Center et Department of Neurosurgery — Hata Kenmin Hospital, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.